Liu Fangchao, Li Jianxin, Chen Jichun, Hu Dongsheng, Li Ying, Huang Jianfeng, Liu Xiaoqing, Yang Xueli, Cao Jie, Shen Chong, Yu Ling, Liu Zhendong, Wu Xianping, Zhao Liancheng, Wu Xigui, Gu Dongfeng, Lu Xiangfeng
Department of Epidemiology, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China; The 3rd Affiliated Hospital of Shenzhen University, Shenzhen 518001, China.
Department of Epidemiology, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.
Sci Bull (Beijing). 2018 Jun 30;63(12):779-787. doi: 10.1016/j.scib.2018.05.020. Epub 2018 May 25.
Evidence on the lifetime risk for atherosclerotic cardiovascular disease (ASCVD) is insufficient; yet, estimating an individual's lifetime risk allows for a comprehensive assessment of ASCVD burden. We developed and validated lifetime risk prediction equations for ASCVD using four large and ongoing prospective cohorts of Chinese, the China-PAR project (Prediction for ASCVD Risk in China). Sex-specific equations were developed using two cohorts (as the derivation cohort) of 21,320 participants. Two other independent cohorts with 14,123 and 70,838 participants were used for their external validation, respectively. We evaluated both calibration and discrimination measures for model performance. Furthermore, we estimated ASCVD-free years lost or excess absolute risk attributable to high 10-year risk (≥10.0%) and/or high lifetime risk (≥32.8%). After 12.3 years' follow-up of the derivation cohort, 1048 ASCVD events and 1304 non-ASCVD deaths were identified. Our sex-specific equations had good internal validation, with discriminant C statistics of 0.776 (95% confidence interval [CI]: 0.757-0.794) and 0.801 (95% CI: 0.778-0.825), and calibration χ of 9.2 (P = 0.418) and 5.6 (P = 0.777) for men and women, respectively. Good external validation was also demonstrated with predicted rates closely matched to the observed ones. Compared with men having both low 10-year and low lifetime risk, men would develop ASCVD 3.0, 4.6 and 8.6 years earlier if they had high 10-year risk alone, high lifetime risk alone, or both high 10-year and high lifetime risk at the index age of 35 years, respectively. We developed well-performed lifetime risk prediction equations that will help to identify those with the greatest potential to avert ASCVD burden after implementation of innovative clinical and public health interventions in China.
关于动脉粥样硬化性心血管疾病(ASCVD)终生风险的证据并不充分;然而,估计个体的终生风险有助于全面评估ASCVD负担。我们利用中国四个大型且正在进行的前瞻性队列(中国PAR项目,即中国ASCVD风险预测项目)开发并验证了ASCVD终生风险预测方程。使用两个队列(共21320名参与者,作为推导队列)分别开发了针对男性和女性的方程。另外两个独立队列(分别有14123名和70838名参与者)用于外部验证。我们评估了模型性能的校准和区分度指标。此外,我们估计了因10年高风险(≥10.0%)和/或终生高风险(≥32.8%)导致的无ASCVD年数损失或额外绝对风险。对推导队列进行12.3年的随访后,共确定了1048例ASCVD事件和1304例非ASCVD死亡。我们针对男性和女性的方程具有良好的内部验证效果,男性的判别C统计量为0.776(95%置信区间[CI]:0.757 - 0.794),校准χ值为9.2(P = 0.418);女性的判别C统计量为0.801(95%CI:0.778 - 0.825),校准χ值为5.6(P = 0.777)。外部验证也显示预测率与观察值紧密匹配。与在35岁时10年风险和终生风险均较低的男性相比,如果仅10年风险高、仅终生风险高或10年风险和终生风险均高,那么他们分别会提前3.0年、4.6年和8.6年发生ASCVD。我们开发了性能良好的终生风险预测方程,这将有助于在中国实施创新的临床和公共卫生干预措施后,识别出那些最有潜力避免ASCVD负担的人群。